These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 10221067)

  • 1. [Drug clinics. Drug of the month. Irbesartan (Aprovel)].
    Kulbertus H
    Rev Med Liege; 1999 Feb; 54(2):125-7. PubMed ID: 10221067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Irbesartan: a new possibility in the treatment of hypertension].
    Rapi J
    Orv Hetil; 2002 May; 143(21):1187-92. PubMed ID: 12073539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist.
    Ruilope L
    J Hypertens Suppl; 1997 Dec; 15(7):S15-20. PubMed ID: 9532516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical overview of irbesartan: expanding the therapeutic window in hypertension.
    Man in't Veld AJ
    J Hypertens Suppl; 1997 Dec; 15(7):S27-33. PubMed ID: 9532518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition of irbesartan, an angiotensin II AT1-receptor antagonist, in mice, rats, rabbits, and macaques.
    Davi H; Tronquet C; Miscoria G; Perrier L; DuPont P; Caix J; Simiand J; Berger Y
    Drug Metab Dispos; 2000 Jan; 28(1):79-88. PubMed ID: 10611144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A look through the new therapeutic window: irbesartan.
    Waeber B; Brunner HR
    J Hypertens Suppl; 1998 Sep; 16(7):S11-6. PubMed ID: 9855026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irbesartan for hypertension.
    Med Lett Drugs Ther; 1998 Jan; 40(1019):18-9. PubMed ID: 9465857
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical overview of irbesartan: a new angiotensin II receptor antagonist.
    Pouleur HG
    Am J Hypertens; 1997 Dec; 10(12 Pt 2):318S-324S. PubMed ID: 9438776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetics and pharmacodynamics of irbesartan in heart failure.
    Kostis JB; Vachharajani NN; Hadjilambris OW; Kollia GD; Palmisano M; Marino MR
    J Clin Pharmacol; 2001 Sep; 41(9):935-42. PubMed ID: 11549097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis.
    Hope S; Brecher P; Chobanian AV
    Am J Hypertens; 1999 Jan; 12(1 Pt 1):28-34. PubMed ID: 10075381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with angiotensin II receptor antagonists.
    Brunner HR; Christen Y; Munafo A; Lee RJ; Waeber B; Nussberger J
    Am J Hypertens; 1992 Dec; 5(12 Pt 2):243S-246S. PubMed ID: 1290619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations.
    Brunner HR
    Am J Hypertens; 1997 Dec; 10(12 Pt 2):311S-317S. PubMed ID: 9438775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irbesartan: review of pharmacology and comparative properties.
    Adams MA; Trudeau L
    Can J Clin Pharmacol; 2000; 7(1):22-31. PubMed ID: 10822210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension.
    Gillis JC; Markham A
    Drugs; 1997 Dec; 54(6):885-902. PubMed ID: 9421695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure.
    Havranek EP; Thomas I; Smith WB; Ponce GA; Bilsker M; Munger MA; Wolf RA
    J Am Coll Cardiol; 1999 Apr; 33(5):1174-81. PubMed ID: 10193713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacological properties and clinical efficacy of the long-active angiotensin receptor blocker (ARB) irbesartan].
    Ariyoshi Y; Mizumoto K
    Nihon Yakurigaku Zasshi; 2009 May; 133(5):275-80. PubMed ID: 19443965
    [No Abstract]   [Full Text] [Related]  

  • 17. Fimasartan, a novel angiotensin II receptor antagonist.
    Kim JH; Lee JH; Paik SH; Kim JH; Chi YH
    Arch Pharm Res; 2012 Jul; 35(7):1123-6. PubMed ID: 22864732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay.
    Belz GG; Butzer R; Kober S; Mang C; Mutschler E
    Clin Pharmacol Ther; 1999 Oct; 66(4):367-73. PubMed ID: 10546920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irbesartan treatment in hypertension.
    Brown MJ
    Hosp Med; 1998 Oct; 59(10):808-11. PubMed ID: 9850301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
    Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.